Serveur d'exploration sur la grippe en Espagne

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.

Identifieur interne : 000242 ( Main/Exploration ); précédent : 000241; suivant : 000243

Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.

Auteurs : Isabel Cortés [Espagne] ; Santiago Pérez-Camarero ; Juan Del Llano ; Luz María Pe A ; Alvaro Hidalgo-Vega

Source :

RBID : pubmed:23764534

Descripteurs français

English descriptors

Abstract

OBJECTIVE

The objective of this survey was to describe the evolution of economic evaluation studies on vaccines available in Spain.

METHODS

We conducted a systematic review of the economic evaluations published by Spanish researchers in major bibliographic databases available online from 1990 to 2012. For all references identified, we limited them to full economic evaluation carried out in Spanish vaccine programs. The following variables were analyzed: type of study, year of publication, vaccine evaluated, the herd immunity and the main methodological aspects proposed by international guidelines. The type of vaccines studied were Hepatitis A and B, Rotavirus, Influenza, Varicella, Tetanus, Measles, Human papillomavirus, Streptococcus pneumoniae infection and Neisseria meningitides serogroup C infection.

RESULTS

A total of 34 references was included in the study. The number of economic evaluations has been increasing over the years by 86%. For many of the vaccines there were no economic evaluations, while others such as the vaccine against S. pneumoniae infection took up most of the studies. The non-vaccinated comparison was the most used strategy. The cost-effectiveness model was selected in 60% of cases. The most common health outcome was "cost per case prevented" and in 82% of the studies did not consider herd immunity. The results showed a cost-effectiveness ratio which was below breakeven.

CONCLUSIONS

It is clear that the existence of a huge gap in this kind of work compared to other countries. Although the quality of the work discussed here was significant, we found many areas which could be improved. The reviewed literature exposed the great benefit of vaccination for society by analysing the health outcomes achieved for decades since its implementation. However, the evidence on the efficiency and effectiveness vaccination is not very high, and there are few studies about economic evaluation.


DOI: 10.1016/j.vaccine.2013.05.097
PubMed: 23764534


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.</title>
<author>
<name sortKey="Cortes, Isabel" sort="Cortes, Isabel" uniqKey="Cortes I" first="Isabel" last="Cortés">Isabel Cortés</name>
<affiliation wicri:level="3">
<nlm:affiliation>Instituto Max Weber, Majadahonda, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Instituto Max Weber, Majadahonda, Madrid</wicri:regionArea>
<placeName>
<settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Perez Camarero, Santiago" sort="Perez Camarero, Santiago" uniqKey="Perez Camarero S" first="Santiago" last="Pérez-Camarero">Santiago Pérez-Camarero</name>
</author>
<author>
<name sortKey="Del Llano, Juan" sort="Del Llano, Juan" uniqKey="Del Llano J" first="Juan" last="Del Llano">Juan Del Llano</name>
</author>
<author>
<name sortKey="Pe A, Luz Maria" sort="Pe A, Luz Maria" uniqKey="Pe A L" first="Luz María" last="Pe A">Luz María Pe A</name>
</author>
<author>
<name sortKey="Hidalgo Vega, Alvaro" sort="Hidalgo Vega, Alvaro" uniqKey="Hidalgo Vega A" first="Alvaro" last="Hidalgo-Vega">Alvaro Hidalgo-Vega</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23764534</idno>
<idno type="pmid">23764534</idno>
<idno type="doi">10.1016/j.vaccine.2013.05.097</idno>
<idno type="wicri:Area/Main/Corpus">00238</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00238</idno>
<idno type="wicri:Area/Main/Curation">000238</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000238</idno>
<idno type="wicri:Area/Main/Exploration">000238</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.</title>
<author>
<name sortKey="Cortes, Isabel" sort="Cortes, Isabel" uniqKey="Cortes I" first="Isabel" last="Cortés">Isabel Cortés</name>
<affiliation wicri:level="3">
<nlm:affiliation>Instituto Max Weber, Majadahonda, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Instituto Max Weber, Majadahonda, Madrid</wicri:regionArea>
<placeName>
<settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Perez Camarero, Santiago" sort="Perez Camarero, Santiago" uniqKey="Perez Camarero S" first="Santiago" last="Pérez-Camarero">Santiago Pérez-Camarero</name>
</author>
<author>
<name sortKey="Del Llano, Juan" sort="Del Llano, Juan" uniqKey="Del Llano J" first="Juan" last="Del Llano">Juan Del Llano</name>
</author>
<author>
<name sortKey="Pe A, Luz Maria" sort="Pe A, Luz Maria" uniqKey="Pe A L" first="Luz María" last="Pe A">Luz María Pe A</name>
</author>
<author>
<name sortKey="Hidalgo Vega, Alvaro" sort="Hidalgo Vega, Alvaro" uniqKey="Hidalgo Vega A" first="Alvaro" last="Hidalgo-Vega">Alvaro Hidalgo-Vega</name>
</author>
</analytic>
<series>
<title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Bacterial Vaccines (economics)</term>
<term>Bacterial Vaccines (immunology)</term>
<term>Bacterial Vaccines (therapeutic use)</term>
<term>Communicable Disease Control (economics)</term>
<term>Communicable Diseases (economics)</term>
<term>Communicable Diseases (immunology)</term>
<term>Cost-Benefit Analysis (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunity, Herd (MeSH)</term>
<term>Mass Vaccination (economics)</term>
<term>Spain (MeSH)</term>
<term>Vaccination (economics)</term>
<term>Viral Vaccines (economics)</term>
<term>Viral Vaccines (immunology)</term>
<term>Viral Vaccines (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Analyse coût-bénéfice (MeSH)</term>
<term>Contrôle des maladies transmissibles (économie)</term>
<term>Espagne (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunité de groupe (MeSH)</term>
<term>Maladies transmissibles (immunologie)</term>
<term>Maladies transmissibles (économie)</term>
<term>Vaccination (économie)</term>
<term>Vaccination de masse (économie)</term>
<term>Vaccins antibactériens (immunologie)</term>
<term>Vaccins antibactériens (usage thérapeutique)</term>
<term>Vaccins antibactériens (économie)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins antiviraux (usage thérapeutique)</term>
<term>Vaccins antiviraux (économie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en">
<term>Bacterial Vaccines</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Bacterial Vaccines</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Bacterial Vaccines</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en">
<term>Communicable Disease Control</term>
<term>Communicable Diseases</term>
<term>Mass Vaccination</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Maladies transmissibles</term>
<term>Vaccins antibactériens</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Communicable Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Vaccins antibactériens</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr">
<term>Contrôle des maladies transmissibles</term>
<term>Maladies transmissibles</term>
<term>Vaccination</term>
<term>Vaccination de masse</term>
<term>Vaccins antibactériens</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Immunity, Herd</term>
<term>Spain</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Analyse coût-bénéfice</term>
<term>Espagne</term>
<term>Humains</term>
<term>Immunité de groupe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>OBJECTIVE</b>
</p>
<p>The objective of this survey was to describe the evolution of economic evaluation studies on vaccines available in Spain.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>METHODS</b>
</p>
<p>We conducted a systematic review of the economic evaluations published by Spanish researchers in major bibliographic databases available online from 1990 to 2012. For all references identified, we limited them to full economic evaluation carried out in Spanish vaccine programs. The following variables were analyzed: type of study, year of publication, vaccine evaluated, the herd immunity and the main methodological aspects proposed by international guidelines. The type of vaccines studied were Hepatitis A and B, Rotavirus, Influenza, Varicella, Tetanus, Measles, Human papillomavirus, Streptococcus pneumoniae infection and Neisseria meningitides serogroup C infection.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>RESULTS</b>
</p>
<p>A total of 34 references was included in the study. The number of economic evaluations has been increasing over the years by 86%. For many of the vaccines there were no economic evaluations, while others such as the vaccine against S. pneumoniae infection took up most of the studies. The non-vaccinated comparison was the most used strategy. The cost-effectiveness model was selected in 60% of cases. The most common health outcome was "cost per case prevented" and in 82% of the studies did not consider herd immunity. The results showed a cost-effectiveness ratio which was below breakeven.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>CONCLUSIONS</b>
</p>
<p>It is clear that the existence of a huge gap in this kind of work compared to other countries. Although the quality of the work discussed here was significant, we found many areas which could be improved. The reviewed literature exposed the great benefit of vaccination for society by analysing the health outcomes achieved for decades since its implementation. However, the evidence on the efficiency and effectiveness vaccination is not very high, and there are few studies about economic evaluation.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23764534</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>04</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>31</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2013</Year>
<Month>Aug</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.</ArticleTitle>
<Pagination>
<MedlinePgn>3473-84</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2013.05.097</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(13)00725-1</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this survey was to describe the evolution of economic evaluation studies on vaccines available in Spain.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review of the economic evaluations published by Spanish researchers in major bibliographic databases available online from 1990 to 2012. For all references identified, we limited them to full economic evaluation carried out in Spanish vaccine programs. The following variables were analyzed: type of study, year of publication, vaccine evaluated, the herd immunity and the main methodological aspects proposed by international guidelines. The type of vaccines studied were Hepatitis A and B, Rotavirus, Influenza, Varicella, Tetanus, Measles, Human papillomavirus, Streptococcus pneumoniae infection and Neisseria meningitides serogroup C infection.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 34 references was included in the study. The number of economic evaluations has been increasing over the years by 86%. For many of the vaccines there were no economic evaluations, while others such as the vaccine against S. pneumoniae infection took up most of the studies. The non-vaccinated comparison was the most used strategy. The cost-effectiveness model was selected in 60% of cases. The most common health outcome was "cost per case prevented" and in 82% of the studies did not consider herd immunity. The results showed a cost-effectiveness ratio which was below breakeven.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">It is clear that the existence of a huge gap in this kind of work compared to other countries. Although the quality of the work discussed here was significant, we found many areas which could be improved. The reviewed literature exposed the great benefit of vaccination for society by analysing the health outcomes achieved for decades since its implementation. However, the evidence on the efficiency and effectiveness vaccination is not very high, and there are few studies about economic evaluation.</AbstractText>
<CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cortés</LastName>
<ForeName>Isabel</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Instituto Max Weber, Majadahonda, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pérez-Camarero</LastName>
<ForeName>Santiago</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Del Llano</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peña</LastName>
<ForeName>Luz María</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hidalgo-Vega</LastName>
<ForeName>Alvaro</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>06</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001428">Bacterial Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D001428" MajorTopicYN="N">Bacterial Vaccines</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D032521" MajorTopicYN="N">Immunity, Herd</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Economic analysis</Keyword>
<Keyword MajorTopicYN="N">Economic evaluation</Keyword>
<Keyword MajorTopicYN="N">Inmunopreventable diseases</Keyword>
<Keyword MajorTopicYN="N">Review</Keyword>
<Keyword MajorTopicYN="N">Spain</Keyword>
<Keyword MajorTopicYN="N">Vaccines</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>03</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2013</Year>
<Month>05</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2013</Year>
<Month>05</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23764534</ArticleId>
<ArticleId IdType="pii">S0264-410X(13)00725-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2013.05.097</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Espagne</li>
</country>
<region>
<li>Communauté de Madrid</li>
</region>
<settlement>
<li>Madrid</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Del Llano, Juan" sort="Del Llano, Juan" uniqKey="Del Llano J" first="Juan" last="Del Llano">Juan Del Llano</name>
<name sortKey="Hidalgo Vega, Alvaro" sort="Hidalgo Vega, Alvaro" uniqKey="Hidalgo Vega A" first="Alvaro" last="Hidalgo-Vega">Alvaro Hidalgo-Vega</name>
<name sortKey="Pe A, Luz Maria" sort="Pe A, Luz Maria" uniqKey="Pe A L" first="Luz María" last="Pe A">Luz María Pe A</name>
<name sortKey="Perez Camarero, Santiago" sort="Perez Camarero, Santiago" uniqKey="Perez Camarero S" first="Santiago" last="Pérez-Camarero">Santiago Pérez-Camarero</name>
</noCountry>
<country name="Espagne">
<region name="Communauté de Madrid">
<name sortKey="Cortes, Isabel" sort="Cortes, Isabel" uniqKey="Cortes I" first="Isabel" last="Cortés">Isabel Cortés</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000242 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000242 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeEspagneV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23764534
   |texte=   Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23764534" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeEspagneV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Fri Sep 25 11:01:38 2020. Site generation: Sat Feb 13 17:38:04 2021